Gyre Therapeutics has finalized its acquisition of Cullgen Inc. in a significant all-stock transaction valued at approximately $300 million. This strategic merger creates a commercial-stage biopharmaceutical company dedicated to advancing therapies for fibrosis and inflammatory diseases. The combined entity will leverage a dual presence in the United States and China to accelerate its global growth strategy.
Strategic Rationale and Integration
The acquisition aims to build a fully integrated biopharmaceutical company with a comprehensive development spectrum. It merges Gyre's commercial product and late-stage pipeline with Cullgen's innovative discovery platform for targeted protein degraders. This combination establishes a powerful entity capable of moving from initial research to market-ready treatments for chronic diseases.
A key aspect of the merger is the operational synergy between the U.S. and China. The company will benefit from a strengthened U.S. leadership team while utilizing its China-based operations for cost-efficient discovery and development. This strategic footprint is designed to support the company's long-term global expansion and therapeutic innovation.
Leadership and Corporate Structure
The new leadership team reflects the integration of both companies' strengths. Dr. Ying Luo, formerly the Chief Executive Officer of Cullgen, has been appointed President and CEO of the combined company. Ping Zhang will provide strategic continuity by remaining as the Chairman of Gyre's Board of Directors.
Following the transaction's closing, Cullgen now operates as a wholly owned subsidiary of Gyre Therapeutics. The combined company will continue to be publicly traded on the Nasdaq Capital Market under its existing ticker symbol, GYRE. This structure ensures a seamless transition for investors and maintains the company's presence in the public market.
A Strengthened Product Pipeline
The merger significantly enhances the company's late-stage clinical portfolio, led by the promising drug candidate F351. This treatment for chronic hepatitis B-induced liver fibrosis recently received priority review status from China's national drug authority. Gyre is also actively exploring the expansion of F351's development into ex-China territories, including the United States.
Gyre's existing commercial asset, ETUARY®, continues to be a cornerstone of its portfolio for treating lung fibrosis in China. The company is advancing its development through Phase 3 trials for new indications like pneumoconiosis and radiation-induced lung injury. These efforts aim to broaden the therapeutic reach and impact of its flagship product.
The addition of Cullgen's technology introduces a robust pipeline of targeted protein degrader and degrader-antibody conjugate therapies. This innovative discovery engine is designed to eliminate therapeutically relevant proteins with high selectivity and potency. These assets are expected to fortify Gyre's portfolio and drive long-term value for the company.
The acquisition of Cullgen for $300 million marks a transformative step for Gyre Therapeutics, establishing it as a formidable player in biopharmaceuticals. By integrating a commercial product, a diverse late-stage pipeline, and a cutting-edge discovery platform, the company is well-equipped for future success. This strategic combination positions Gyre to deliver innovative treatments for fibrosis and inflammatory diseases on a global scale.